Heart saver: Comprehensive investigation of (redox-) proteomic and thiol metabolite changes induced by Cana-, Dapa-, Empagliflozin treatment in 2D and 3D heart cell models reveals increased mitochondrial activity and glutathione redox defense and involvement of redox signaling
Abstract
AIMS: Antidiabetic drugs, sodium-glucose co-transporter-2 inhibitors (SGLT-2i), have demonstrated heart-saving properties independently of the diabetes status of a patient. We aimed to discover SGLT-2i-specific cardiac targets.
MATERIALS AND METHODS: Two cardiac cell lines (AC16 and HCM) were treated with low-end therapeutic and 100- or 1000-fold dose of cana-, dapa and empagliflozin to investigate their influence on the (redox) proteome and thiol metabolome. Furthermore, we mimicked reperfusion injury (RI) on stem-cell derived cardioids to examine if and how SGLT-2i help to cope with RI.
KEY FINDINGS: We show that gliflozins increase glutathione synthesis and trigger autophagy already at low drug concentration, visible through increase in ATG13. On the (redox) proteome level, several potential targets could be identified: 10 proteins affected by low concentration across all three drugs (including TXN and NAPRT) in HCM cells and 16 downregulated proteins shared between all high drug treatments in HCM cells and cardioids. Among the latter were GSR, PRDX2, LAMTOR5 and the catalytic subunit of PP2A. On the redox proteome level, we found among others, PKM, PPP1CA, PRDX5 and MDH2 with redox affected cysteine sites in both HCM and AC16 cells, and additionally, PKM, MDH2 and PPP2CA in both HCM and cardioids.
SIGNIFICANCE: Our data suggest that gliflozin treatments affect the cells' capacity to buffer redox stress by increasing glutathione and altering redox state of key cysteine…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.